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Summary
Introduction: The primary tumour type most likely to metastasize to the brain is
lung cancer. In heavily pre-treated patients, limited therapeutic option is available
and the results of availability therapies reported in literature are disappointing. The
present phase II study was designed to assess the efﬁcacy and safety of temozolo-
mide (TMZ) as palliative treatment for brain metastases (BrM) in NSCLC patients
pre-treated with WBRT and at least one line of chemotherapy for metastatic brain
disease.
Material and methods: Temozolomide was administered orally at 150mg/mq/day
for ﬁve consecutive days for the ﬁrst cycle, doses were increased to 200mg/mq/day
for 5 days every 28 days for subsequent cycles if no grade 3/4 haematological toxi-
city was observed. Eligibility criteria included cytological or histological conﬁrmed
NSCLC; BrM, recurrent or progressing after WBRT and at least one line of chemother-
apy. A total of 30 consecutive patients entered the study and received the allocated
treatment.
Results: Three patients (10%) achieved an objective response (OR) of BrM with
two complete remission. Stable disease and progressive disease were achieved
in 3 (10%) and 24 patients (80%), respectively. A correlation between response to TMZ
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and sensitivity to the previous ﬁrst line chemotherapy was reported. Time to pro-
gression and overall survival were examined both for responder patients and for all
included patients. For long-term survivors, we considered the patients who survived
>12 months after the start of TMZ. According to this deﬁnition, three patients resulted
long-term survivors: 2 with OR and 1 with stable brain disease. No grades 3 or 4 toxi-
city occurred. The total of treatment-related adverse events were mild or moderate
(G1-2) in intensity. No patients discontinued TMZ as a result of treatment-related
toxicity.
Discussion: The results of the present trial clearly demonstrates that TMZ is active
and safe in BrM NSCLC patients previously treated with WBRT and at least one line of
chemotherapy.
© 2005 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Among intra-cranial tumours, brain metastases
(BrM) are more common than primary brain
tumours. The primary tumour type most likely to
metastasize to the brain is lung cancer. Among
patients affected by advanced NSCLC up to 40%
have BrM identiﬁable at autopsy [1]. Whole brain
radiotherapy (WBRT) improves neurological symp-
toms in about 50% of patients and lengthens the
median survival from 3 to 6m
suggest that epipodophilloto
with cisplatin are very effec
related BrM and ifosfamide
or gemcitabine—cisplatin co
evaluated with similar go
Temozolomide (TMZ) is a
lating agent with virtual
ity [10—12]. It is a new
eration imidazotetrazine p
goes spontaneous convers
cal conditions to the active alkylating agent-
MTIC, thus not requiring hepatic metabolism to
2. Patients and methods
2.1. Patients eligibility
Eligibility criteria included cytological or histolog-
ical conﬁrmed NSCLC; BrM, in progression after
WBRT and at least one previous line of chemother-
apy for metastatic brain disease. Patients were also
required to have evaluable or measurable brain dis-
ease assessed by CT or MRI scans, age between
required. Patients could have no other synchronous
tumors except for non-melanoma skin cancer or in
situ cervical carcinoma, if appropriately treated.
Exclusions criteria included: uncontrolled life-
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tbecome active. It crosses the blood—brain bar-
rier and has showed activity in heavily pre-
treated patients affected by BrM from NSCLC
[10—12]. Concentrations of the drug in the cen-
tral nervous system reach approximately 30—40%
of plasma concentrations and clearance of TMZ
is unaffected by co-administration with anticon-
vulsivants, antiemetics or dexamethasone. TMZ
also has a good toxicity proﬁle. The dose-
limiting toxicity is not cumulative myelosuppres-
sion that rarely requires treatment delay or dose
reduction.
The present phase II study was designed to
assess the efﬁcacy and safety of TMZ as pallia-
tive treatment for recurrent or progressing BrM
in NSCLC patients pre-treated with WBRT and at
least one line of chemotherapy for metastatic brain
disease.hreatening systemic disease, pregnant or lactating
omen and patients not willing to use effective
ethods of contraception. Written informed con-
ent from each patient had to be obtained before
atient entry. Patients were excluded if adequate
ollow-up was not possible (environmental or geo-
raphic difﬁculties, no compliance to undergo nec-
ssary clinical—instrumental investigations, etc.).
.2. Study schedule and evaluations
creening assessments including medical history,
hysical examination (including vital signs, height,
eight and KPS), neurological functional status
Table 1), electrocardiogram (ECG), chest X-ray and
umor measurements, based on the appropriateonths [2]. Recent trials
xins alone or combined
tive in treating NSCLC-
—mitomycin—cisplatin
mbinations have been
od responses [3—9].
novel, oral, alky-
ly 100% bioavailabil-
class of second gen-
ro-drugs that under-
ion under physiologi-
18 and 80 years, an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status ≤2 and a
life expectance >3 months. Bone marrow function
requirements included an absolute neutrophil count
≥1500mm−3, a platelet count ≥100,000mm−3 and
hemoglobin ≥10.0 g/100mL. Preserved renal func-
tion (serum creatinine ≤1.5mg/dL, normal crea-
tinine clearance), hepatic function (total biliru-
bin ≤1.5mg/dL, AST and ALT ≤2.5 times normal
without hepatic metastasis and ≤4 times normal
with hepatic metastasis) and cardiac function were
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Table 1 Neurological functional status
Level 1 Fully functional
Level 2 Fully functional not able to work
Level 3 Stays in bed-need help half the time
Level 4 Need help full time
imaging techniques (i.e. CT and/or MRI scan of the
brain, CT scan of the chest and upper abdomen,
radionuclide bone scan) were conducted within 14
days before treatment initiation. Laboratory data
including complete blood count, blood chemistry
and urinalysis were also obtained. Monthly eval-
uations included a complete history, neurological
examination, assessment of performance status and
toxicity.
All pre-treatment imaging procedures, with
exclusion of radionuclide bone scan, were repeated
every two cycles. All tumor measurements were
reviewed and conﬁrmed by an independent panel of
radiologists and oncologists. The primary study end
point was radiological response of BrM. Responses
for measurable lesions were reported according
WHO criteria. Responses for evaluable lesions were
scored by a four-point grade system: no evidence of
tumour, better, unchanged, worse. Secondary end
points were, safety, tolerability and overall sur-
vival.
Overall survival was calculated from inclusion
date to record of death for any cause.
2.3. Treatment plan and toxicity and dose
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greater hepatic toxicity, elevation of transaminases
or alkaline phosphatase had to be resolved to at
least a grade 1 prior to repeat dosing. Patients
with repeated grades 3 and 4 non-haematological
toxicity were taken off study.
Full haematological recovery was required for
re-treatment. Patients could remain on treatment
until disease progression (evaluated with the best
instrumental exams applicable in case of metastatic
lesions after at least three cycles and every three
cycles) or the development of unacceptable tox-
icity (according to the National Cancer Institute
Bethesda Common Toxicity Criteria, NCI-CTC [13])
or patient’s refusal.
2.4. Statistical methods
The efﬁcacy analysis were based on the intent-to-
treat population. The primary efﬁcacy end point
was objective tumor response, deﬁned as a CR or
PR. The 95% CI for response risk was calculated.
According to the method of Fleming, a sample
size of 30 patients was required to demonstrate a
response rate within ±10% with a power of 90%.
Safety and survival were secondary end points. Sur-
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Aodiﬁcations
emozolomide was administered orally at
50mg/mq/day for ﬁve consecutive days for the
rst cycle, doses were increased to 200mg/mq/day
or 5 days every 28 days for subsequent cycles if no
rade 3/4 haematological toxicity was observed.
rophylactic antiemetics were administered before
he patient ingested TMZ. Steroids were adminis-
ered at the lowest dose required by neurological
tatus. Anticonvulsivants were given when indi-
ated. Adverse reaction were evaluated according
o the National Cancer Institute Bethesda Common
oxicity Criteria, NCI-CTC [13]. Cumulative toxicity
as evaluated and noted before each treatment
ycle. Blood cell counts and the liver/renal func-
ion were assessed 21 days after the ﬁrst dose
f TMZ. The TMZ dose for subsequent cycles was
djusted according to nadir counts with dose levels
f 150 or 100mg/mq/day. In case of grade 2 or
reater non-haematological toxicity, patients were
o be treated at the lower dose level except for
lopecia, nausea, vomiting. In case of grade 2 orival time was deﬁned as the time from initiation
f treatment to the date of death. To determine
hether objective tumor response was associated
ith improved survival, a landmark analysis was
erformed. All analyses were descriptive. Statisti-
al analyses for baseline demographics, response
ates and adverse events were descriptive. Safety
as analyzed in all patients who received at least
ne dose of study medication (Table 2).
. Results
.1. Patient characteristics
he demographic and baseline disease characteris-
ics of the evaluable patients are listed in Table 3.
A total of 30 consecutive patients entered the
tudy and received the allocated treatment from
ctober 2000 to July 2003. All patients were
re-treated with WBRT (30Gy in 10 fractions of
00 cGy) and at least one line of chemotherapy
or metastatic brain disease (18/30 and 5/30 of
atients with second and third line of chemother-
py, respectively, for metastatic disease, regard-
ess of brain disease). The median interval from
BRT to start TMZ was 12 weeks (range 4—48
eeks). The median interval from last chemother-
py to start TMZ was 10 weeks (range 4—16 weeks)
median of six cycles (range 2—36) of TMZ was
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Table 2 Patients demographics and baseline disease
characteristics
Characteristics No. of
patients (%)
Total number 30
Male/female 23/7
Age (years)
Median 65
Range 45—79
Performance status
ECOG 0 7 (23.3)
ECOG 1 19 (63.3)
ECOG 2 4 (13.4)
RPA Class II 20
RPA Class III 4
Brain metastases
Single 5 (16.7)
Multiple 25 (83.3)
Other metastatic sites 30 (100)
Bone 5 (16.7)
Lymph nodes 24 (80.0)
Liver 1 (3.3)
Lung 8 (26.6)
Other 14 (46.7)
Neurological function evaluation
Level 1 25 (83.4)
Level 2 4 (13.3)
Level 3 1 (3.3)
Previous treatment
WBRT 30 (100)
Stereotactic radiosurgery 1 (3.3)
Chemotherapy (ﬁrst line for
brain metastases)
30 (100)
Cisplatin-based 17 (56.7)
Carboplatin-based 11 (36.7)
Taxane-based 11 (36.7)
Vinorelbine-based 6 (20.0)
Values in parenthesis are percentages.
administered to patients for a total of 180 cycles.
The median dose for patient was 5550mg/mq
(range 1750—34,750mg/mq). The median duration
of therapy was 6 months (range 2—36 months). All
patients were assessable for treatment efﬁcacy and
safety.
3.2. Antitumor efﬁcacy
Three patients (10%; 95% CI 7.6—13.4) achieved an
objective response (OR) of BrM with two complete
remission. Stable disease and progressive disease
were achieved in 3 (10%) and 24 patients (80%),
respectively (Table 3). When responses were
deﬁned according to the criteria of MacDonald at
el. [14], all responses were conﬁrmed. Further-
more, in one patient with cytologically conﬁrmed
meningitis carcinomatosis, cerebrospinal ﬂuid
was cleared after two cycles of TMZ and stable
disease for 6 months was obtained. A baseline
functional assessment before the start of treat-
ment demonstrated that neurological functional
status was level 1 (with ECOG PS 0) in ﬁve and
two (with ECOG PS 1) in one of the six patients
with objective response or stable disease after
TMZ administration. The RPA class was two in all
responders patients. The neurological status was
1 (2 patients), 2 (18 patients) and 3 (4 patients) in
patients with progressive brain disease after TMZ.
Moreover, a correlation between response to TMZ
and sensitivity to the previous ﬁrst line chemother-
apy was reported. In fact, objective radiological
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Table 3 Survival of patients according to brain lesion resp
Response, No. of patients (%) Time to progression (mo
Complete response, 2 (6.7) 19 (12.1—25.9)
Partial response, 1 (3.3) 11 (8.4—13.6)
Stable disease, 3 (10.0) 4 (2.9—6.4)
Progressive disease, 24 (80.0) 1.5 (0.8—2.7)
All patients 3.6 (0.8—25.9)esponse or stable brain disease was achieved in six
atients with chemo-sensitive NSCLC (with partial
esponse-3 patients — or stable disease-3 patients
after ﬁrst line chemotherapy for metastatic
isease regardless brain disease). Among patients
ith primary refractory disease, deﬁned as failure
f ﬁrst line chemotherapy in inducing a complete
r partial response or in stabilizing the disease,
o remission or stabilization of brain disease was
chieved with TMZ. In patients with OR of brain dis-
ase, the median time to progression was 19 (95%
I 12.1—25.9) and 11 (95% CI 8.4—13.6) months for
R and PR, respectively. Stable extracranial disease
with one minimal response) were reported in 4/6
atients with remission or stabilization of brain
isease. Notably, progressive disease outside the
rain was reported, during the following follow-up,
n all six responders patients with a concomitant
ersistence of objective radiological response
r stable brain disease. Five of these patients
eceived TMZ in association with Docetaxel (TXT)
onse to treatment
nths) (95% CI) Overall survival (months) (95% CI)
24 (12.1—35.9)
14 (10.9—17.1)
8 (6.7—11.9)
3 (1.9—4.6)
6 (1.9—35.9)
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or Gemcitabine chemotherapy after TMZ alone,
obtaining three PR of extra-brain measurable dis-
ease. Progressive extracranial disease was reported
in all patients who brain disease progressed. Time
to progression and overall survival were examined
both for responder patients and for all included
patients at the median follow-up of 22 months
(range 3—31 months) (Table 3). Regarding the two
patients with complete remission of BrM, one died
24 months after WBRT for leukoencephalopathy
(with absence of BrM and stable extra-cranial
disease) and the second (presenting extra-cranial
progressive disease 32 months after WBRT) is still
alive 42 months after radiotherapy (Fig. 1). For
F
l
(ig. 1 Magnetic resonance imaging of one metastatic brain le
ung cancer at baseline (6 months after end of WBRT) (A) and 4
B). Persistent complete remission of brain disease.sion in the brain of a 60-year-old man with non-small cell
0 months after the start of treatment with temozolomide
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long-term survivors, we considered the patients
who survived >12 months after the start of TMZ.
According to this deﬁnition, three patients resulted
long-term survivors: two with OR and one with
stable brain disease. Between the long-term sur-
vivors patients, two died for cerebral atrophy and
leucoencephalopathy with persistent radiological
response of BrM and stable extra-cranial disease.
3.3. Safety results
Safety was recorded for all 30 patients enrolled
in this study. During the treatment the percentage
of patients who required corticosteroid decreased
from 100 to 67%. No grades 3 or 4 toxicity occurred.
The treatment-related adverse events were mild
or moderate (G1-2) in intensity. Myelosuppression
was minimal and non-cumulative. Other events
included fatigue, constipation, headache (not nec-
essarily related to treatment) and mild to mod-
erate nausea, which was easily controlled with
standard antiemetic medications. Dose reductions
were required in only eight patients (26.7%): for
headache in two patients (6.7%) and for fatigue in
six patients (20.0%). Although most patients discon-
still controversial. However, among patients with
NSCLC and BrM, response to different chemother-
apy regimens, such cisplatin—gemcitabine or
cisplatin—ifosfamide—irinotecan, was similar to
that achieved in other disease sites [3—9]. Instead,
for patients with recurrent or persistent BrM after
WBRT and at least one line of chemotherapy,
the treatment options available are limited. In
two phase II trials of TMZ in heavily pre-treated
patients the treatment was safe and well toler-
ated and showed clinical activity in patients with
BrMs from NSCLC [21,22]. In 52 patients, with pro-
gressive brain metastases after WBRT, three partial
responses (two in lung cancer patients and one in
patient with melanoma) were reported with TMZ
by Friedman et al. [23]. For newly diagnosed brain
metastases, a preliminary report by Siena et al.
showed an overall response (partial response plus
stable disease) of 24% with TMZ monotherapy in
patient with NSCLC as primitive tumour [24]. Anton-
odau et al. in a randomized phase II study and in
a conﬁrmatory phase III study comparing TMZ plus
WBRT to WBRT alone in population largely consist-
ing of lung cancer patients, reported a signiﬁcantly
greater overall response in the patients receiving
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stinued TMZ treatment because of disease progres-
sion, none of them discontinued it as a result of
treatment-related toxicity.
4. Discussion
Brain metastases from NSCLC are associated with
poor prognosis despite aggressive treatment. Also,
the majority of patients suffer debilitating neu-
rological symptoms. The optimal treatment for
patients with BrM continues to evolve. The recur-
sive partitioning analysis (RPA) of prognostic factors
in three Radiation Therapy Oncology Group brain
metastases trials identiﬁed three prognostic classes
with median survival of 2.3 months (RPA Class III)
to 7.1 months (RPA Class I). [15] Although WBRT
remains the mainstay of the treatment for BrM
from NSCLC, surgical therapy, possibly followed by
WBRT, may be considered the treatment of choice
for patient with single resectable BrM, especially
for younger patients with a good performance sta-
tus and satisfactory control of extra-cranial dis-
ease [16—19]. Furthermore, a statistically signiﬁ-
cant improvement in median survival with the addi-
tion of radiosurgery to WBRT was seen for patients
with single brain metastasis, RPA class I patients
[20]. For patients with multiple symptomatic BrM,
WBRT is often the treatment of choice. The role
of chemotherapy in patients with BrM by NSCLC isMZ [25,26]. Instead, in a preliminary report of
erger et al., a response of only 16% was noted with
BRT plus TMZ in 85 patients, half of whom had
ung cancer [27]. Furthermore, in two phase II stud-
es TMZ was reported to be inactive or marginally
ctive in NSCLC [28,29]. In one review, van de Bent
oncluded that the available data not justify the
se of TMZ in patients with BrMs from NSCLC out-
ide of clinical trials [30]. The present phase II
tudy assessed the activity and safety of TMZ in
eavily pre-treated NSCLC patients with BrMs. The
esults of this trial suggest that treatment with TMZ
s safe and quite active: 6/30 patients achieved
bjective response or stable disease of BrM and
he adverse events associated with TMZ are mod-
st, reversible and generally predictable. A cor-
elation between response to TMZ and sensitivity
o ﬁrst line chemotherapy was reported: none of
he patients with chemo-refractory NSCLC achieved
bjective radiological response of BrM or stable
rain disease after TMZ. Remarkably 3/30 patients,
n the present trial, resulted long-term survivors.
hree patients reported neurocognitive deteriora-
ions. Two patients died for severe neurological
omplications related to WBRT. Long-term seque-
as of WBRT comprise neurocognitive deterioration
nd dementia induced by leukoencephalopathy and
erebral atrophy or necrosis [31] All patients were
re-treated with a short course of large-fraction RT
30Gy in 10 fractions) and large, daily RT fraction
izes are associated with increase risk of neurocog-
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nitive deﬁcits [32]. In the vast majority of patients
with metastatic brain disease the survival is short
and patients not survive long enough to develop
cognitive deﬁcits from RT but the few long-term
survivors usually develop cognitive deﬁcits from
WBRT with large fraction size [32].
However, the results of the present trial demon-
strates that TMZ is quite active, but safe in BrM
NSCLC patients previously treated with WBRT and
at least one line of chemotherapy. In this particular
setting of patients, the results and safety reported
in literature are disappointing and limited thera-
peutic option are available. In conclusion, these
results clearly do re-enforce the concept of utility
of second and following lines chemotherapy regi-
mens and highlight the need for new trials to verify
the real clinical impact of TMZ versus supportive
care in patients with NSCLC and metastatic brain
disease progressing or recurrent after WBRT and at
least one line of chemotherapy.
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